Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs). METHODS: Eligible patients received daily temozolomide (50 mg/m(2)) continuously until progression. The primary endpoint was progression-free...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Omuro, Antonio, Chan, Timothy A., Abrey, Lauren E., Khasraw, Mustafa, Reiner, Anne S., Kaley, Thomas J., DeAngelis, Lisa M., Lassman, Andrew B., Nolan, Craig P., Gavrilovic, Igor T., Hormigo, Adilia, Salvant, Cynthia, Heguy, Adriana, Kaufman, Andrew, Huse, Jason T., Panageas, Katherine S., Hottinger, Andreas F., Mellinghoff, Ingo
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2013
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548585/
https://ncbi.nlm.nih.gov/pubmed/23243055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos295
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars